Drug Profile
Anti-HGF monoclonal antibody L2G7
Alternative Names: Anti-HGF mAb L2G7; HuL2G7; L2G7; TAK-701Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Galaxy Biotech LLC
- Developer Galaxy Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Hepatocyte growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 31 Jul 2012 Anti-HGF monoclonal antibody L2G7 is available for licensing as of 31 Jul 2012. http://www.galaxybiotech.com
- 31 Jul 2012 Anti-HGF monoclonal antibody L2G7 is no longer licensed to Takeda